Toxicity and cosmesis outcomes after single fraction partial breast irradiation in early stage breast cancer

Paola Pinnarò, Stefano Arcangeli, Carolina Giordano, Giorgio Arcangeli, Fabrizio Ambesi Impiombato, Valentina Pinzi, Giuseppe Iaccarino, Antonella Soriani, Valeria Landoni, Lidia Strigari, Paola Pinnarò, Stefano Arcangeli, Carolina Giordano, Giorgio Arcangeli, Fabrizio Ambesi Impiombato, Valentina Pinzi, Giuseppe Iaccarino, Antonella Soriani, Valeria Landoni, Lidia Strigari

Abstract

Background: To report the clinical outcome after a Single Shot 3D-CRT PBI (SSPBI) in breast cancer patients after conservative surgery (ClinicalTrials.gov Identifier: NCT01316328).

Methods: A dose of 18 Gy (in the first 4 patients) and 21 Gy (in the remaining 60 patients) was prescribed in a single session and delivered to the index area (i.e. the area of breast including the primary tumor bed and the surrounding tissue) using 3D-CRT with patients in prone position. Acute and late toxicity was assessed using the National Cancer Institute's CTC for Adverse Events. Cosmesis was defined based on modified Harvard criteria. Differences between dosimetric or clinical parameters of patients with/without G2 or more late toxicity or unsatisfactory (poor or fair) cosmetic outcome were evaluated with the Mann-Whitney test. Odds ratios and 95% confidence interval were calculated for cosmesis and fibrosis. Univariate and multivariate analyses(UVA/MVA) were used to determine covariates associated with an increase in fibrosis or fat necrosis rate.

Results: Sixty four patients were enrolled. With a median follow-up of 3 years, G2 and G3 subcutaneous fibrosis was detected in 20(31%) and in 8(13%) patients, and ≥G2 fat necrosis was observed in 2(3%) patients. Good to excellent, fair and poor cosmesis was observed in 38(59%), 23(36%) and 3(5%) patients, respectively. Based on UVA, the breast volume receiving more than 21 Gy (V21 Gy) was found to be a predictor of the ≥G1 or ≥G2 fibrosis/fat necrosis. Based on MVA, V21 Gy was confirmed as a predictor for ≥G1 fibrosis/fat necrosis, the results correlated as a trend for ≥G2. Cosmesis was correlated with whole breast (WB) mean dose (p=0.030).

Conclusion: Our choice of a single dose of 21 Gy significantly increased the treatment related toxicity. However, this should not discourage novel SSPBI approaches with lower equivalent doses.

Figures

Figure 1
Figure 1
Positioning device and patient preparation. Positioning device hooked to the a) CT simulator and b) Varian treatment couch with PMMA frames with a 15 cm diameter circular opening placed inside the table top, c) PMMA frames with different diameters and positions, d)Patient preparation: the contra-lateral breast was bandaged, the pads are glued to the skin by their adhesive area, when the patient lies on the table the plastic bolts are inserted inside the corresponding holes and the breast is fixed to the table by nuts.
Figure 2
Figure 2
Contours and clips on CT slices. a) CT slice with clips, CTV, PTV and OARs, including INBV = ipsilateral normal breast volume, IBSV = ipsilateral breast skin volume. b) fields arrangement.
Figure 3
Figure 3
Dose distribution. Dose distribution in a representative patient in a) trasversal, b) coronal, c) sagittal plane. PTV outlined in black. Some surgical clips are visible.
Figure 4
Figure 4
Treatment setup verification by portal imaging. Treatment setup verification by portal imaging. a) Image acquired with gantry at 90 degrees. b) portal image matched with the DRR image. The breast correct position is verified by lead marker and breast profile alignment.
Figure 5
Figure 5
G3 fat necrosis. Mammographic image of G3 fat necrosis observed in 1 patient.
Figure 6
Figure 6
Photographs of cosmetic outcome. Photographs a)before and b) after RT of a patient with excellent cosmetic outcome; photographs c),e),g) before and d),f),h) after RT of three patients with poor cosmetic outcome. The cosmetic outcome was defined according to modified Harvard criteria (see text).

References

    1. Veronesi U, Marubini E, Mariani L, Galimberti V, Luini A, Veronesi P, Salvadori B, Zucali R. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001;12:997–1003. doi: 10.1023/A:1011136326943.
    1. Fisher ER, Anderson S, Redmond C, Fisher B. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NASBP protocol B-06. Semin Surg Oncol. 1992;8:161–166.
    1. Schnitt SJ, Abner A, Gelman R, Connolly JL, Recht A, Duda RB, Eberlein TJ, Mayzel K, Silver B, Harris JR. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer. 1994;74:1746–1751. doi: 10.1002/1097-0142(19940915)74:6<1746::AID-CNCR2820740617>;2-Y.
    1. R. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer. 1994;74:1746–1751. doi: 10.1002/1097-0142(19940915)74:6<1746::AID-CNCR2820740617>;2-Y. conservatively treated.Eur.J.Cancer 2001, 37:2178-2183.
    1. Baglan KL, Sharpe MB, Jaffray D. et al.Accelerated partial breast irradiation using 3D conformal radiation therapy (3D-CRT) Int J Radiat Oncol Biol Phys. 2003;55(2):302–11. doi: 10.1016/S0360-3016(02)03811-7.
    1. Vicini FA, Remouchamps V, Wallace M. et al.Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2003;57(5):1247–53. doi: 10.1016/S0360-3016(03)01573-6.
    1. Vicini F, Winter K, Straube W, Wong J, Pass H, Rabinovitch R, Chafe S, Arthur D, Petersen I, McCormick B. A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for Stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) Study 0319. Int J Radiat Oncol Biol Phys. 2005;63(5):1531–7. doi: 10.1016/j.ijrobp.2005.06.024. Epub 2005 Sep 29.
    1. Formenti SC, Rosenstein B, Skinner KA, Jozsef G. T1 stage breast cancer: Adjuvant hypofractionated conformal radiation therapy to tumor bed in selected postmenopausal breast cancer patients-Pilot feasibility study. Radiology. 2002;222:171–178.
    1. Polgár C, Major T, Fodor J, Németh G, Orosz Z, Sulyok Z, Udvarhelyi N, Somogyi A, Takácsi-Nagy Z, Lövey K, Agoston P, Kásler M. High dose rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast conserving surgery: Seven year results of a comparative study. Int J Radiat Oncol Biol Phys. 2004;60:1173–1181. doi: 10.1016/j.ijrobp.2004.05.012.
    1. Vaidya JS, Tobias JS, Baum M, Wenz F, Kraus-Tiefenbacher U, D'souza D, Keshtgar M, Massarut S, Hilaris B, Saunders C, Joseph D. TARGeted Intraoperative radioTherapy (TARGIT):An Innovative Approach to Partial-Breast Irradiation. Semin Radiat Oncol. 2005;15:84–91. doi: 10.1016/j.semradonc.2004.10.007.
    1. Vicini FA, Arthur DW. Breast Brachytherapy: North American Experience. Semin Radiat Oncol. 2005;15:108–115. doi: 10.1016/j.semradonc.2004.10.005.
    1. Shah NM, Wazer DE. The MammoSite Balloon Brachytherapy Catheter for Accelerated Partial Breast Irradiation. Semin Radiat Oncol. 2005;15:100–107. doi: 10.1016/j.semradonc.2004.10.006.
    1. Pignol JP, Keller B, Rakovitch E, Sankreacha R, Easton H, Que W. First report of a permanent breast 103Pd seed implant as adjuvant radiation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2006;64:176–181. doi: 10.1016/j.ijrobp.2005.06.031.
    1. Formenti SC. External-Beam Partial-Breast Irradiation. Semin Radiat Oncol. 2005;15:92–99. doi: 10.1016/j.semradonc.2004.10.008.
    1. Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, Hollis D, Lind P, Tisch A, Wong TZ, Borges-Neto S. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005;63:214–223. doi: 10.1016/j.ijrobp.2005.01.029.
    1. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6:557–565. doi: 10.1016/S1470-2045(05)70251-5.
    1. Valagussa P, Zambetti M, Biasi S, Moliterni A, Zucali R, Bonadonna G. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol. 1994;5:209–216.
    1. Shapiro CL, Hardenbergh PH, Gelman R, Blanks D, Hauptman P, Recht A, Hayes DF, Harris J, Henderson IC. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998;16:3493–3501.
    1. Iaccarino G, Pinnaro P, Landoni V, Marzi S, Soriani A, Giordano C, Arcangeli S, Benassi M, Arcangeli G. Single fraction partial breast irradiation in prone position. J Exp Clin Cancer Res. 2007;26(4):543–52.
    1. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181. doi: 10.1016/S1053-4296(03)00031-6.
    1. Lövey K, Fodor J, Major T, Szabó E, Orosz Z, Sulyok Z, Jánváry L, Fröhlich G, Kásler M, Polgár C. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy:4-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:724–731. doi: 10.1016/j.ijrobp.2007.03.055.
    1. Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange JR, Jacobs LK, Emens LA, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, Wolff AC. Feasibility Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide in Early-Stage Breast Cancer. J Clin Oncol. pp. 2816–2822.
    1. Fowler J. The linear quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:672–695.
    1. Veronesi U, Orecchia R, Luini A, Galimberti V, Zurrida S, Intra M, Veronesi P, Arnone P, Leonardi MC, Ciocca M, Lazzari R, Caldarella P, Rotmensz N, Sangalli C, Sances D, Maisonneuve P. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat. 2010;124:141–151. doi: 10.1007/s10549-010-1115-5.
    1. Wazer DE, Kaufman S, Cuttino L, DiPetrillo T, Arthur DW. Accelerated partial breast irradiation: An analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64:489–495. doi: 10.1016/j.ijrobp.2005.06.028.
    1. Kuske RR, Winter K, Arthur DW, Bolton J, Rabinovitch R, White J, Hanson W, Wilenzick RM. A phase II trial of brachytherapy alone following lumpectomy for select breast cancer:Toxicity analysis of Radiation Therapy Oncology Group 95-17. Int J Radiat Oncol Biol Phys. 2006;65:45–51. doi: 10.1016/j.ijrobp.2005.11.027.
    1. Chen PY, Vicini FA, Benitez P, Kestin LL, Wallace M, Mitchell C, Pettinga J, Martinez AA. Long-term cosmetic results and toxicity after accelerated partial breast irradiation. Cancer. 2006;106:991–999. doi: 10.1002/cncr.21681.
    1. Vicini FA, Beitsch PD, Quiet CA, Keleher A, Garcia D, Snider HC, Gittleman MA, Zannis VJ, Kuerer H, Whitacre EB, Whitworth PW, Fine RE, Haffty BG, Arrambide LS. First analysis of patient demographics, technical reproducibility, cosmesis and early toxicity by the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial in 793 patients treated with accelerated partial breast irradiation (APBI) Cancer. 2005;104:1138–1148. doi: 10.1002/cncr.21289.
    1. Benitez PR, Keisch ME, Vicini F, Stolier A, Scroggins T, Walker A, White J, Hedberg P, Hebert M, Arthur D, Zannis V, Quiet C, Streeter O, Silverstein M. Five year results:The initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg. 2007;194:456–462. doi: 10.1016/j.amjsurg.2007.06.010.
    1. Berrang TS, Olivotto I, Kim DH, Nichol A, John Cho BC, Mohamed IG, Parhar T, Wright JR, Truong P, Tyldesley S, Sussman J, Wai E, Whelan T. Three-Year Outcomes of a Canadian Multicenter Study of Accelerated Partial Breast Irradiation Using Conformal Radiation Therapy. Int J Radiat Oncol Biol Phys. 2010. in press .
    1. Shaitelman SF, Kim LH, Grills IS, Chen PY, Ye H, Kestin LL, Yan D, Vicini FA. Predictors of long-term toxicity using three-dimensional conformal external beam radiotherapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010. in press .
    1. Chen PY, Wallace M, Mitchell C, Grills I, Kestin L, Fowler A, Martinez A, Vicini F. Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76:991–997. doi: 10.1016/j.ijrobp.2009.03.012.
    1. Jagsi R, Ben-David MA, Moran JM, Marsh RB, Griffith KA, Hayman JA, Pierce LJ. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76:71–78. doi: 10.1016/j.ijrobp.2009.01.041.
    1. Hepel JT, Tokita M, MacAusland SG, Evans SB, Hiatt JR, Price LL, DiPetrillo T, Wazer DE. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009;75:1290–96. doi: 10.1016/j.ijrobp.2009.01.009.
    1. Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376(9735):91–102. doi: 10.1016/S0140-6736(10)60837-9.
    1. Lemanski C, Azria D, Gourgon-Bourgade S, Gutowski M, Rouanet P, Saint-Aubert B, Ailleres N, Fenoglietto P, Dubois JB. Intraoperative radiotherapy in early-stage breast cancer: results of the montpellier phase II trial. Int J Radiat Oncol Biol Phys. 2010;76(3):698–703. doi: 10.1016/j.ijrobp.2009.02.039.
    1. Palta M, Yoo S, Adamson JD, Prosnitz LR, Horton JK. Preoperative single fraction partial breast radiotherapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2010. in press .
    1. Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad W, Mueller RP, Kurtz J, Morgan DA, Dubois JB, Salamon E, Mirimanoff R, Bolla M, Van der Hulst M, Wárlám-Rodenhuis CC, Bartelink H. EORTC Radiation Oncology Group. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: A study based on the EORTC Trial 22881- 10882 ''boost versus no boost''. Eur J Cancer. 2008;44:2587–99. doi: 10.1016/j.ejca.2008.07.032.
    1. Bentzen SM, Yarnold JR. Reports of unexpected late side effects of accelerated partial breast irradiation -- radiobiological considerations. Int J Radiat Oncol Biol Phys. 2010;77:969–973. doi: 10.1016/j.ijrobp.2010.01.059.
    1. Bentzen SM, Overgaard M, Thames HD, Christensen JJ, Overgaard J. Early and late normal-tissue injury after postmastectomy radiotherapy alone or combined with chemotherapy. Int J Radiat Biol. 1989;56:711–715. doi: 10.1080/09553008914551941.
    1. Hall E. Radiobiology for the radiologist. Philadelphia: Lippincott Williams & Wilkins; 2000.
    1. Steel GG. Basic clinical radiobiology. Eduard Arnold Publisher. 1995.
    1. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, Perera F, Fyles A, Schneider K, Gulavita S, Freeman C. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20. doi: 10.1056/NEJMoa0906260.
    1. The START Trialists' Group. The UK Standardisation of breast radiotherapy(START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol. 2008;9:331–341.
    1. The START Trialists' Group. The UK Standardisation of breast radiotherapy(START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet. 2008;371:1098–1107.
    1. Falvo E, Strigari L, Citro G, Giordano C, Arcangeli S, Soriani A, D'Alessio D, Muti P, Blandino G, Sperduti I, Pinnarò P. Dose and polymorphic genes xrcc1, xrcc3, gst play a role in the risk of developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. BMC Cancer. 2011;11:291. doi: 10.1186/1471-2407-11-291.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe